Reports and Insights (R&I) has published a new report titled, “Small Bowel Cancer Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028”
Small Bowel Cancer Treatment Market, by Type (Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to gain traction over the forecast period between 2020 and 2028.
The global small bowel cancer treatment market in 2020 is estimated for more than US$ 13.7 Bn and expected to reach a value of US$ 16.6 Bn by 2028 with a significant CAGR of 2.4%
As per the report, Cancer is a disorder that is characterized by the unchecked and uncontrollable division and survival of abnormal cells. When such abnormal growth occurs under the colon or rectum, it is called colorectal cancer.
According to the American Cancer Society, In 2017, it is estimated that around 95,000 new cases of colon cancer and around 40,000 cases of rectal cancer were diagnosed in the U.S. having gender-wise distribution as 47,700 in men and 47,820 in women. Whereas, in the case of rectal cancer around 24,000 in male and 16,000 female were diagnosed. In 2017, among all the diagnosed patients around 27,000 male and 23,000 female died from small bowel cancer.
The data may be not accurate due to the reporting as around 40% of the death from rectal cancer were reported as death from colon cancer in the death certificate. The wrong educational messaging is a major reason for the inaccurate recording in the data due to the misclassification leading to confusion between the word colon cancer and colorectal cancer as colon cancer refers to both colon and rectal cancer. Smoking is one of the major factors that support the rise in the number of small bowel cancer patients globally this in turn has increased the incidence rate in male.
Furthermore, Reports and Insights (R&I) Study identifies that around 10% of all cancers are colorectal cancers, which makes this site the third most common after lung cancer and breast cancer. In high-income countries, small bowel cancer stands on the seventh spot as a leading cause of death with around 30 Bn USD in spending over the small bowel cancer treatment.
According to the World Health Organization, in 2030, colorectal cancer can be the 14th leading cause of death worldwide. There have been several reasons that affect the conversion of the adenomatous polyp, or adenoma into invasive cancer such as the high consumption of red meat and salted and smoked food may damage the intestinal lining and can promote the growth of polys inside the colon.
Along with that one of the important factor on which researchers are inclined is the presence of an autoimmune disease known as Crohn’s disease, which affects the gastrointestinal tract and may finally lead to colorectal cancer.
Furthermore, Familial adenomatous polyposis (FAP), is also one of the supporting reasons that are expected to underpin the rise in growth for the small bowel cancer treatment market in the near future. People suffering from cystic fibrosis may indirectly create a risk of intestinal cancer and finally to small bowel cancer due to food and enzyme disbalance.
R&I Study identifies some of the key participating players in small bowel cancer treatment market globally are Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca Plc and Pfizer Inc., and among others.
Reports and Insights (R&I) is committed to providing deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: [email protected]
For New Topics and Other Info: [email protected]